Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Blaker YN"'
Autor:
Bai B; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; KG Jebsen Centre for B-cell malignancies, Institute for Clinical Medicine, University of Oslo, Oslo, Norway.; Department of Clinical Molecular Biology (EpiGen),, Akershus University Hospital, Lørenskog, Norway., Wise JF; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; KG Jebsen Centre for B-cell malignancies, Institute for Clinical Medicine, University of Oslo, Oslo, Norway.; Norwegian Cancer Genomics Consortium, CancerGenomics.no, Oslo, Norway.; Massachusetts General Hospital Cancer Center and Department of Pathology, Harvard Medical School, Charlestown, MA, USA.; Broad Institute of Harvard and MIT, Cambridge, MA, USA., Vodák D; Norwegian Cancer Genomics Consortium, CancerGenomics.no, Oslo, Norway.; Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway., Nakken S; Norwegian Cancer Genomics Consortium, CancerGenomics.no, Oslo, Norway.; Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; Centre for Cancer Cell Reprogramming, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.; Centre for Bioinformatics, University of Oslo, Oslo, Norway., Sharma A; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; KG Jebsen Centre for B-cell malignancies, Institute for Clinical Medicine, University of Oslo, Oslo, Norway.; Precision Immunotherapy Alliance, University of Oslo, Oslo, Norway., Blaker YN; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; KG Jebsen Centre for B-cell malignancies, Institute for Clinical Medicine, University of Oslo, Oslo, Norway., Brodtkorb M; KG Jebsen Centre for B-cell malignancies, Institute for Clinical Medicine, University of Oslo, Oslo, Norway.; Department of Oncology, Division for Cancer Medicine, Oslo University Hospital, Oslo, Norway., Hilden V; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; KG Jebsen Centre for B-cell malignancies, Institute for Clinical Medicine, University of Oslo, Oslo, Norway.; Precision Immunotherapy Alliance, University of Oslo, Oslo, Norway., Trøen G; Department of Pathology, Oslo University Hospital, Oslo, Norway., Ren W; Division of Immunology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden., Lorenz S; Norwegian Cancer Genomics Consortium, CancerGenomics.no, Oslo, Norway.; Genomics Core Facility, Department of Core Facilities, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway., Lawrence MS; Massachusetts General Hospital Cancer Center and Department of Pathology, Harvard Medical School, Charlestown, MA, USA.; Broad Institute of Harvard and MIT, Cambridge, MA, USA., Myklebost O; Norwegian Cancer Genomics Consortium, CancerGenomics.no, Oslo, Norway.; Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; Department for Clinical Science, University of Bergen, Bergen, Norway., Kimby E; Unit for Hematology and Department of Medicine at Karolinska Institutet, Huddinge, Stockholm, Sweden., Pan-Hammarström Q; Division of Immunology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden., Steen CB; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; KG Jebsen Centre for B-cell malignancies, Institute for Clinical Medicine, University of Oslo, Oslo, Norway.; Precision Immunotherapy Alliance, University of Oslo, Oslo, Norway., Meza-Zepeda LA; Norwegian Cancer Genomics Consortium, CancerGenomics.no, Oslo, Norway.; Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; Genomics Core Facility, Department of Core Facilities, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway., Beiske K; Department of Pathology, Oslo University Hospital, Oslo, Norway., Smeland EB; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; KG Jebsen Centre for B-cell malignancies, Institute for Clinical Medicine, University of Oslo, Oslo, Norway., Hovig E; Norwegian Cancer Genomics Consortium, CancerGenomics.no, Oslo, Norway.; Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; Centre for Bioinformatics, University of Oslo, Oslo, Norway., Lingjærde OC; KG Jebsen Centre for B-cell malignancies, Institute for Clinical Medicine, University of Oslo, Oslo, Norway.; Department of Informatics, University of Oslo, Oslo, Norway.; Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway., Holte H; KG Jebsen Centre for B-cell malignancies, Institute for Clinical Medicine, University of Oslo, Oslo, Norway. hhe@ous-hf.no.; Norwegian Cancer Genomics Consortium, CancerGenomics.no, Oslo, Norway. hhe@ous-hf.no.; Department of Oncology, Division for Cancer Medicine, Oslo University Hospital, Oslo, Norway. hhe@ous-hf.no., Myklebust JH; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway. j.h.myklebust@medisin.uio.no.; KG Jebsen Centre for B-cell malignancies, Institute for Clinical Medicine, University of Oslo, Oslo, Norway. j.h.myklebust@medisin.uio.no.; Precision Immunotherapy Alliance, University of Oslo, Oslo, Norway. j.h.myklebust@medisin.uio.no.
Publikováno v:
Blood cancer journal [Blood Cancer J] 2024 Aug 27; Vol. 14 (1), pp. 147. Date of Electronic Publication: 2024 Aug 27.
Autor:
Spasevska I; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; KG Jebsen Centre for B-cell malignancies, Institute of Clinical Medicine, University of Oslo, Norway.; Precision Immunotherapy Alliance, University of Oslo, Oslo, Norway., Sharma A; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; KG Jebsen Centre for B-cell malignancies, Institute of Clinical Medicine, University of Oslo, Norway.; Precision Immunotherapy Alliance, University of Oslo, Oslo, Norway., Steen CB; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; KG Jebsen Centre for B-cell malignancies, Institute of Clinical Medicine, University of Oslo, Norway.; Precision Immunotherapy Alliance, University of Oslo, Oslo, Norway.; Division of Oncology, Stanford University School of Medicine, Stanford, CA., Josefsson SE; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; KG Jebsen Centre for B-cell malignancies, Institute of Clinical Medicine, University of Oslo, Norway., Blaker YN; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; KG Jebsen Centre for B-cell malignancies, Institute of Clinical Medicine, University of Oslo, Norway., Kolstad A; KG Jebsen Centre for B-cell malignancies, Institute of Clinical Medicine, University of Oslo, Norway.; Department of Oncology, Innlandet Hospital Trust, Lillehammer, Norway.; Division of Cancer Medicine, Department of Oncology, Oslo University Hospital, Oslo, Norway., Rustad EH; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; Precision Immunotherapy Alliance, University of Oslo, Oslo, Norway., Meyer S; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; Precision Immunotherapy Alliance, University of Oslo, Oslo, Norway., Isaksen K; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; KG Jebsen Centre for B-cell malignancies, Institute of Clinical Medicine, University of Oslo, Norway.; Precision Immunotherapy Alliance, University of Oslo, Oslo, Norway., Chellappa S; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway., Kushekhar K; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; KG Jebsen Centre for B-cell malignancies, Institute of Clinical Medicine, University of Oslo, Norway., Beiske K; KG Jebsen Centre for B-cell malignancies, Institute of Clinical Medicine, University of Oslo, Norway.; Division of Cancer Medicine, Department of Pathology, Oslo University Hospital, Oslo, Norway., Førsund MS; Division of Cancer Medicine, Department of Pathology, Oslo University Hospital, Oslo, Norway., Spetalen S; Division of Cancer Medicine, Department of Pathology, Oslo University Hospital, Oslo, Norway., Holte H; KG Jebsen Centre for B-cell malignancies, Institute of Clinical Medicine, University of Oslo, Norway.; Division of Cancer Medicine, Department of Oncology, Oslo University Hospital, Oslo, Norway., Østenstad B; KG Jebsen Centre for B-cell malignancies, Institute of Clinical Medicine, University of Oslo, Norway.; Division of Cancer Medicine, Department of Oncology, Oslo University Hospital, Oslo, Norway., Brodtkorb M; KG Jebsen Centre for B-cell malignancies, Institute of Clinical Medicine, University of Oslo, Norway.; Division of Cancer Medicine, Department of Oncology, Oslo University Hospital, Oslo, Norway., Kimby E; Department of Hematology, Karolinska Institute, Stockholm, Sweden., Olweus J; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; Precision Immunotherapy Alliance, University of Oslo, Oslo, Norway.; Institute of Clinical Medicine, University of Oslo, Norway., Taskén K; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; KG Jebsen Centre for B-cell malignancies, Institute of Clinical Medicine, University of Oslo, Norway., Newman AM; Division of Oncology, Stanford University School of Medicine, Stanford, CA.; Divisions of Hematology & Oncology, Department of Medicine, Stanford University, Stanford, CA., Lorenz S; Department of Core Facilities, Geonomics Core Facility, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway., Smeland EB; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; KG Jebsen Centre for B-cell malignancies, Institute of Clinical Medicine, University of Oslo, Norway.; Precision Immunotherapy Alliance, University of Oslo, Oslo, Norway., Alizadeh AA; Division of Oncology, Stanford University School of Medicine, Stanford, CA.; Divisions of Hematology & Oncology, Department of Medicine, Stanford University, Stanford, CA., Huse K; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; KG Jebsen Centre for B-cell malignancies, Institute of Clinical Medicine, University of Oslo, Norway.; Precision Immunotherapy Alliance, University of Oslo, Oslo, Norway., Myklebust JH; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; KG Jebsen Centre for B-cell malignancies, Institute of Clinical Medicine, University of Oslo, Norway.; Precision Immunotherapy Alliance, University of Oslo, Oslo, Norway.
Publikováno v:
Blood advances [Blood Adv] 2023 Dec 12; Vol. 7 (23), pp. 7216-7230.
Autor:
Meriranta L; Research Programs Unit, Applied Tumor Genomics, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; Department of Oncology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.; iCAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland., Alkodsi A; Research Programs Unit, Applied Tumor Genomics, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; iCAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland., Pasanen A; Research Programs Unit, Applied Tumor Genomics, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; Department of Oncology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.; iCAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland., Lepistö M; Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science HILIFE, Helsinki, Finland., Mapar P; Research Programs Unit, Applied Tumor Genomics, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; iCAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland.; Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science HILIFE, Helsinki, Finland., Blaker YN; Department of Oncology, Oslo University Hospital and KG Jebsen Centre for B Cell Malignancies, Oslo, Norway., Jørgensen J; Department of Hematology, Aarhus University Hospital, Aarhus, Denmark., Karjalainen-Lindsberg ML; Department of Pathology, Helsinki University Hospital, Helsinki, Finland., Fiskvik I; Department of Radiology and Nuclear Medicine., Mikalsen LTG; Department of Diagnostic Physics, Oslo University Hospital, Oslo, Norway.; Department of Life Sciences and Health, Oslo Metropolitan University, Oslo, Norway., Autio M; Research Programs Unit, Applied Tumor Genomics, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; Department of Oncology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.; iCAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland., Björkholm M; Department of Medicine, Karolinska University Hospital, Stockholm, Sweden., Jerkeman M; Division of Oncology, Skane University Hospital, Lund, Sweden., Fluge Ø; Department of Oncology, Haukeland University Hospital, Bergen, Norway., Brown P; Department of Hematology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark; and., Jyrkkiö S; Department of Oncology, Turku University Hospital, Turku, Finland., Holte H; Department of Oncology, Oslo University Hospital and KG Jebsen Centre for B Cell Malignancies, Oslo, Norway., Pitkänen E; Research Programs Unit, Applied Tumor Genomics, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; iCAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland.; Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science HILIFE, Helsinki, Finland., Ellonen P; Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science HILIFE, Helsinki, Finland., Leppä S; Research Programs Unit, Applied Tumor Genomics, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; Department of Oncology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.; iCAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland.
Publikováno v:
Blood [Blood] 2022 Mar 24; Vol. 139 (12), pp. 1863-1877.
Autor:
Isaksen KT; Department of Cancer Immunology Institute for Cancer Research Oslo University Hospital Oslo Norway.; KG Jebsen Centre for B cell malignancies University of Oslo Oslo Norway.; Institute of Clinical Medicine University of Oslo Oslo Norway., Beiske K; Institute of Clinical Medicine University of Oslo Oslo Norway.; Department of Pathology Oslo University Hospital Oslo Norway., Smeland EB; Department of Cancer Immunology Institute for Cancer Research Oslo University Hospital Oslo Norway.; KG Jebsen Centre for B cell malignancies University of Oslo Oslo Norway., Jørgensen J; Department of Hematology Aarhus University Hospital Aarhus Denmark., Brodtkorb M; Department of Cancer Immunology Institute for Cancer Research Oslo University Hospital Oslo Norway.; KG Jebsen Centre for B cell malignancies University of Oslo Oslo Norway., Myklebust JH; Department of Cancer Immunology Institute for Cancer Research Oslo University Hospital Oslo Norway.; KG Jebsen Centre for B cell malignancies University of Oslo Oslo Norway., Jerkeman M; Department of Oncology Lund University and Skåne University Hospital Lund Sweden., Meriranta L; Helsinki University Hospital Comprehensive Cancer Centre and University of Helsinki Helsinki Finland.; iCAN Digital Precision Cancer Medicine Flagship Helsinki Finland., Karjalainen-Lindsberg ML; Department of Pathology Helsinki University Hospital Helsinki Finland., Leppä S; Helsinki University Hospital Comprehensive Cancer Centre and University of Helsinki Helsinki Finland.; iCAN Digital Precision Cancer Medicine Flagship Helsinki Finland., Scott DW; Centre for Lymphoid Cancer British Columbia Cancer Vancouver Canada., Holte H; KG Jebsen Centre for B cell malignancies University of Oslo Oslo Norway.; Department of Oncology Oslo University Hospital Oslo Norway., Blaker YN; Department of Cancer Immunology Institute for Cancer Research Oslo University Hospital Oslo Norway.; KG Jebsen Centre for B cell malignancies University of Oslo Oslo Norway.; Institute of Clinical Medicine University of Oslo Oslo Norway.
Publikováno v:
EJHaem [EJHaem] 2020 Dec 05; Vol. 2 (1), pp. 104-108. Date of Electronic Publication: 2020 Dec 05 (Print Publication: 2021).
Autor:
Wise JF; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; Norwegian Cancer Genomics Consortium, Oslo, Norway.; K. G. Jebsen Centre for B-cell Malignancies, Faculty of Medicine, University of Oslo, Oslo, Norway.; Massachusetts General Hospital Cancer Center, Boston, MA.; Department of Pathology, Harvard Medical School, Charlestown, MA.; Broad Institute of Harvard and MIT, Cambridge, MA., Nakken S; Norwegian Cancer Genomics Consortium, Oslo, Norway.; Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; Institute of Clinical Medicine, Faculty of Medicine.; Centre for Cancer Cell Reprogramming, Institute of Clinical Medicine, Faculty of Medicine, and., Steen CB; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; Department of Informatics, University of Oslo, Oslo, Norway., Vodák D; Norwegian Cancer Genomics Consortium, Oslo, Norway.; Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; Institute of Clinical Medicine, Faculty of Medicine., Trøen G; Department of Pathology and., Johannessen B; Institute of Clinical Medicine, Faculty of Medicine.; Department of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway., Lingjærde OC; Department of Informatics, University of Oslo, Oslo, Norway., Hilden V; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; K. G. Jebsen Centre for B-cell Malignancies, Faculty of Medicine, University of Oslo, Oslo, Norway., Blaker YN; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; K. G. Jebsen Centre for B-cell Malignancies, Faculty of Medicine, University of Oslo, Oslo, Norway.; Institute of Clinical Medicine, Faculty of Medicine., Bai B; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; K. G. Jebsen Centre for B-cell Malignancies, Faculty of Medicine, University of Oslo, Oslo, Norway., Aasheim LB; Norwegian Cancer Genomics Consortium, Oslo, Norway.; Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway., Pasanen A; Department of Oncology, Helsinki University Hospital Cancer Center, Helsinki, Finland.; Research Program Unit, Faculty of Medicine, University of Helsinki, Helsinki, Finland., Lorenz S; Norwegian Cancer Genomics Consortium, Oslo, Norway.; Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; Genomics Core Facility, Department of Core Facilities, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway., Sveen A; Institute of Clinical Medicine, Faculty of Medicine.; Department of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway., Lothe RA; Norwegian Cancer Genomics Consortium, Oslo, Norway.; Institute of Clinical Medicine, Faculty of Medicine.; Department of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway., Myklebost O; Norwegian Cancer Genomics Consortium, Oslo, Norway.; Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; Department for Clinical Science, University of Bergen, Bergen, Norway; and., Leppä S; Department of Oncology, Helsinki University Hospital Cancer Center, Helsinki, Finland.; Research Program Unit, Faculty of Medicine, University of Helsinki, Helsinki, Finland., Meza-Zepeda LA; Norwegian Cancer Genomics Consortium, Oslo, Norway.; Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; Genomics Core Facility, Department of Core Facilities, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway., Beiske K; Institute of Clinical Medicine, Faculty of Medicine.; Department of Pathology and., Lawrence MS; Massachusetts General Hospital Cancer Center, Boston, MA.; Department of Pathology, Harvard Medical School, Charlestown, MA.; Broad Institute of Harvard and MIT, Cambridge, MA., Hovig E; Norwegian Cancer Genomics Consortium, Oslo, Norway.; Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; Department of Informatics, University of Oslo, Oslo, Norway., Myklebust JH; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; K. G. Jebsen Centre for B-cell Malignancies, Faculty of Medicine, University of Oslo, Oslo, Norway., Smeland EB; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; Norwegian Cancer Genomics Consortium, Oslo, Norway.; K. G. Jebsen Centre for B-cell Malignancies, Faculty of Medicine, University of Oslo, Oslo, Norway., Holte H; Norwegian Cancer Genomics Consortium, Oslo, Norway.; K. G. Jebsen Centre for B-cell Malignancies, Faculty of Medicine, University of Oslo, Oslo, Norway.; Department of Oncology, Oslo University Hospital, Oslo, Norway.
Publikováno v:
Blood advances [Blood Adv] 2020 May 12; Vol. 4 (9), pp. 1859-1866.
Autor:
Jakobsen LH; Department of Hematology, Aalborg University Hospital, Aalborg, Denmark.; Department of Clinical Medicine, Aalborg University, Aalborg, Denmark., Ellin F; Department of Clinical Sciences Lund, Oncology, Lund University, Lund, Sweden., Smeland KB; Department of Oncology, Oslo University Hospital, Oslo, Norway., Wästerlid T; Department of Medicine Solna, Division of Clinical Epidemiology, Karolinska Institutet, and Karolinska University Hospital, Stockholm, Sweden., Christensen JH; Department of Hematology, Odense University Hospital, Odense, Denmark., Jørgensen JM; Department of Hematology, Aarhus University Hospital, Aarhus, Denmark., Josefsson PL; Department of Hematology, Herlev Hospital, Herlev, Denmark., Øvlisen AK; Department of Hematology, Aalborg University Hospital, Aalborg, Denmark.; Department of Clinical Medicine, Aalborg University, Aalborg, Denmark., Holte H; Department of Oncology, Oslo University Hospital, Oslo, Norway.; KG Jebsen Centre for B-cell malignancies, Oslo, Norway., Blaker YN; KG Jebsen Centre for B-cell malignancies, Oslo, Norway.; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway., Grauslund JH; Department of Hematology, Roskilde Sygehus, Roskilde, Denmark., Bjørn J; Department of Hematology, Rigshospitalet, Copenhagen, Denmark., Molin D; Experimental and Clinical Oncology, Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden., Lagerlöf I; Division of Drug Research, Department of Medical and Health Sciences, Linköping University, Linköping, Sweden., Smedby KE; Department of Medicine Solna, Division of Clinical Epidemiology, Karolinska Institutet, and Karolinska University Hospital, Stockholm, Sweden., Colvin K; Department of Haematology, Sir Charles Gairdner Hospital, Nedlands, WA, Australia., Thanarajasingam G; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Maurer MJ; Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA., Habermann TM; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Song KW; Leukemia/BMT Program of BC, Centre for Lymphoid Cancer, BC Cancer, Vancouver, Canada., Zhu KY; Leukemia/BMT Program of BC, Centre for Lymphoid Cancer, BC Cancer, Vancouver, Canada., Gerrie AS; Leukemia/BMT Program of BC, Centre for Lymphoid Cancer, BC Cancer, Vancouver, Canada., Cheah CY; Department of Hematology, Sir Charles Gairdner Hospital, Nedlands, Australia.; Department of Hematology, Pathwest Laboratory Medicine WA, Nedlands, Australia.; Medical School, University of Western Australia, Crawley, Australia., El-Galaly TC; Department of Hematology, Aalborg University Hospital, Aalborg, Denmark.; Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.
Publikováno v:
British journal of haematology [Br J Haematol] 2020 May; Vol. 189 (4), pp. 661-671. Date of Electronic Publication: 2020 Feb 04.
Autor:
Köksal H; Division of Cancer Medicine, Department of Cellular Therapy, and., Dillard P; Division of Cancer Medicine, Department of Cellular Therapy, and., Josefsson SE; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; KG Jebsen Centre for B-cell Malignancies, Institute for Clinical Medicine, University of Oslo, Oslo, Norway., Maggadottir SM; Division of Cancer Medicine, Department of Cellular Therapy, and., Pollmann S; Division of Cancer Medicine, Department of Cellular Therapy, and., Fåne A; Division of Cancer Medicine, Department of Cellular Therapy, and., Blaker YN; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; KG Jebsen Centre for B-cell Malignancies, Institute for Clinical Medicine, University of Oslo, Oslo, Norway., Beiske K; KG Jebsen Centre for B-cell Malignancies, Institute for Clinical Medicine, University of Oslo, Oslo, Norway.; Division of Cancer Medicine, Department of Pathology, and., Huse K; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; KG Jebsen Centre for B-cell Malignancies, Institute for Clinical Medicine, University of Oslo, Oslo, Norway., Kolstad A; KG Jebsen Centre for B-cell Malignancies, Institute for Clinical Medicine, University of Oslo, Oslo, Norway.; Division of Cancer Medicine, Department of Oncology, Oslo University Hospital, Oslo, Norway; and.; KG Jebsen Centre for Cancer Immunotherapy, Institute for Clinical Medicine, University of Oslo, Oslo, Norway., Holte H; KG Jebsen Centre for B-cell Malignancies, Institute for Clinical Medicine, University of Oslo, Oslo, Norway.; Division of Cancer Medicine, Department of Oncology, Oslo University Hospital, Oslo, Norway; and., Kvalheim G; Division of Cancer Medicine, Department of Cellular Therapy, and., Smeland EB; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; KG Jebsen Centre for B-cell Malignancies, Institute for Clinical Medicine, University of Oslo, Oslo, Norway., Myklebust JH; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; KG Jebsen Centre for B-cell Malignancies, Institute for Clinical Medicine, University of Oslo, Oslo, Norway., Inderberg EM; Division of Cancer Medicine, Department of Cellular Therapy, and., Wälchli S; Division of Cancer Medicine, Department of Cellular Therapy, and.
Publikováno v:
Blood advances [Blood Adv] 2019 Apr 23; Vol. 3 (8), pp. 1230-1243.
Autor:
Josefsson SE; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; KG Jebsen Centre for B-cell Malignancies, Institute for Clinical Medicine, University of Oslo, Oslo, Norway., Beiske K; Department of Pathology, Division of Cancer Medicine, Oslo University Hospital, Oslo, Norway., Blaker YN; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; KG Jebsen Centre for B-cell Malignancies, Institute for Clinical Medicine, University of Oslo, Oslo, Norway., Førsund MS; Department of Pathology, Division of Cancer Medicine, Oslo University Hospital, Oslo, Norway., Holte H; KG Jebsen Centre for B-cell Malignancies, Institute for Clinical Medicine, University of Oslo, Oslo, Norway.; Department of Oncology, Division of Cancer Medicine, Oslo University Hospital, Oslo, Norway., Østenstad B; Department of Oncology, Division of Cancer Medicine, Oslo University Hospital, Oslo, Norway., Kimby E; Department of Hematology, Karolinska Institutet, Stockholm, Sweden., Köksal H; KG Jebsen Centre for B-cell Malignancies, Institute for Clinical Medicine, University of Oslo, Oslo, Norway.; Section for Cellular Therapy, Department for Cancer Treatment, Oslo University Hospital, Oslo, Norway., Wälchli S; KG Jebsen Centre for B-cell Malignancies, Institute for Clinical Medicine, University of Oslo, Oslo, Norway.; Section for Cellular Therapy, Department for Cancer Treatment, Oslo University Hospital, Oslo, Norway., Bai B; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; KG Jebsen Centre for B-cell Malignancies, Institute for Clinical Medicine, University of Oslo, Oslo, Norway., Smeland EB; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; KG Jebsen Centre for B-cell Malignancies, Institute for Clinical Medicine, University of Oslo, Oslo, Norway., Levy R; Division of Oncology, Stanford School of Medicine, Stanford, California., Kolstad A; Department of Oncology, Division of Cancer Medicine, Oslo University Hospital, Oslo, Norway., Huse K; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; KG Jebsen Centre for B-cell Malignancies, Institute for Clinical Medicine, University of Oslo, Oslo, Norway., Myklebust JH; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway. June.Helen.Myklebust@rr-research.no.; KG Jebsen Centre for B-cell Malignancies, Institute for Clinical Medicine, University of Oslo, Oslo, Norway.
Publikováno v:
Cancer immunology research [Cancer Immunol Res] 2019 Mar; Vol. 7 (3), pp. 355-362. Date of Electronic Publication: 2019 Jan 18.
Autor:
Holte H; Department of Oncology, Oslo University Hospital, Oslo, Norway.; KG Jebsen Centre for B cell malignancies, Institute for Clinical Medicine, University of Oslo, Oslo, Norway., Beiske K; Department of Pathology, Oslo University Hospital, Oslo, Norway., Boyle M; Centre for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver, BC, Canada., Trøen G; Department of Pathology, Oslo University Hospital, Oslo, Norway., Blaker YN; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway., Myklebust J; KG Jebsen Centre for B cell malignancies, Institute for Clinical Medicine, University of Oslo, Oslo, Norway.; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway., Kvaløy S; Department of Surgery, Vestfold Hospital Trust, Oslo, Norway., Rosenwald A; Institute of Pathology, University of Würzburg and Comprehensive Cancer Centre (CCC) Mainfranken, Würzburg, Germany., Lingjaerde OC; Department of Informatics, University of Oslo, Oslo, Norway., Rimsza LM; Laboratory Medicine and Pathology, Mayo Clinic, Scottsdale, AZ, USA., Smeland EB; KG Jebsen Centre for B cell malignancies, Institute for Clinical Medicine, University of Oslo, Oslo, Norway.; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway., Scott DW; Centre for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver, BC, Canada., Kolstad A; Department of Oncology, Oslo University Hospital, Oslo, Norway.; KG Jebsen Centre for Cancer Immunotherapy, Institute for Clinical Medicine, University of Oslo, Oslo, Norway.
Publikováno v:
British journal of haematology [Br J Haematol] 2018 Oct; Vol. 183 (2), pp. 225-234. Date of Electronic Publication: 2018 Aug 06.
Autor:
Federico M; Department of Diagnostic, Clinical and Public Health Medicine, University of Modena and Reggio Emilia, Modena, Italy; Division of Medical Oncology, Città di Lecce Hospital, GVM Care and Research, Lecce, Italy. Electronic address: massimo.federico@unimore.it., Caballero Barrigón MD; Department of Hematology, Complejo Hospitalario Universitario, Instituto Biosanitario (IBSAL), Salamanca, Spain., Marcheselli L; Fondazione Italiana Linfomi, Onlus, University of Modena and Reggio Emilia, Modena, Italy., Tarantino V; Department of Diagnostic, Clinical and Public Health Medicine, University of Modena and Reggio Emilia, Modena, Italy., Manni M; Department of Diagnostic, Clinical and Public Health Medicine, University of Modena and Reggio Emilia, Modena, Italy., Sarkozy C; Hospices Civils de Lyon, Universite Claude Bernard Lyon 1, Department of Haematology, Pierre Benite, France., Alonso-Álvarez S; Department of Haematology, Hospital Universitario Central de Asturias, Asturias, Spain., Wondergem M; Department of Hematology, VU University Medical Center, Amsterdam, Netherlands., Cartron G; Department of Haematology, CHU Montpellier, Montpellier, France., Lopez-Guillermo A; Haematology Department, Hospital Clinic, Barcelona, Spain., Issa D; Department of Haematology, Jeroen Bosch Ziekenhuis, Den Bosch, Netherlands., Morschhauser F; Department of Clinical Haematology, CHU Lille, Unite GRITA, Universite de Lille 2, Lille, France., Alcoceba M; Department of Hematology, Complejo Hospitalario Universitario, Instituto Biosanitario (IBSAL), Salamanca, Spain., Kimby E; Department of Hematology, Karolinska University Hospital and Department of Medicine, Karolinska Institutet, Stockholm, Sweden., Rusconi C; Division of Hematology, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy., Chamuleau M; Department of Hematology, VU University Medical Center, Amsterdam, Netherlands., Holte H; Department of Oncology, Radiumhospitalet, Oslo University Hospital, Oslo, Norway., Lockmer S; Department of Hematology, Karolinska University Hospital and Department of Medicine, Karolinska Institutet, Stockholm, Sweden., Montoto S; Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK., Gomes da Silva M; Instituto Português de Oncologia, Departamento de Hematologia, Lisbon, Portugal., Aurer I; Division of Hematology, Department of Internal Medicine, University Hospital Center Zagreb and Medical School, University of Zagreb, Zagreb, Croatia., Zucca E; Oncology Institute of Southern Switzerland (IOSI), Ospedale San Giovanni, Bellinzona, Switzerland., Paszkiewicz-Kozik E; Department of Lymphoid Malignancies, Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland., Minoia C; Haematology Unit, IRCCS Istituto Tumori 'Giovanni Paolo II', Bari, Italy., Skrypets T; Department of Diagnostic, Clinical and Public Health Medicine, University of Modena and Reggio Emilia, Modena, Italy., Blaker YN; Department of Oncology, Radiumhospitalet, Oslo University Hospital, Oslo, Norway., Salles G; Hospices Civils de Lyon, Universite Claude Bernard Lyon 1, Department of Haematology, Pierre Benite, France., Coiffier B; Hospices Civils de Lyon, Universite Claude Bernard Lyon 1, Department of Haematology, Pierre Benite, France.
Publikováno v:
The Lancet. Haematology [Lancet Haematol] 2018 Aug; Vol. 5 (8), pp. e359-e367. Date of Electronic Publication: 2018 Jul 04.